Avicenna Biosciences employs a machine learning (ML)-driven medicinal chemistry platform that focuses on the critical stage of Lead Optimization in drug development. This innovative approach aims to streamline the transition from promising clinical candidates to viable drugs, significantly reducing development costs and time to market. By utilizing proprietary ML methods, Avicenna can rapidly identify new chemical entities, addressing common challenges such as off-target toxicity and poor pharmacokinetics. Their platform has demonstrated remarkable efficiency, achieving a 100-fold reduction in synthetic effort and successfully discovering the first orally available, CNS-penetrant ROCK inhibitor for neurodegenerative diseases within just 12 months.

The company has made significant strides in developing potent and selective ROCK inhibitors, with candidates like AVI-009 and AVI-016 showing promising therapeutic benefits in animal models for conditions such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS). Avicenna's approach not only enhances the likelihood of identifying candidates with favorable ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties but also positions them as a valuable collaborator for pharmaceutical and biotechnology companies seeking to optimize their drug development efforts. Through these advancements, Avicenna aims to accelerate the journey from drug discovery to life-saving therapeutics.

United States

Avicenna Biosciences was founded to solve the intractable challenges that previously stopped drug candidates in their tracks.  We have created an ML-driven medicinal chemistry platform that makes Lead Optimization faster, cheaper, and more successful – transforming sub-optimal development candidates into life-saving drugs.  The platform has seen rapid success in discovering the first orally available, CNS-penetrant ROCK inhibitors for the treatment of neurodegenerative diseases, with IND-enabling studies initiated just one year since the program kicked off.

Avicenna Biosciences

Company Details